Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 59

Time to Lose Consciousness With Remimazolam vs Propofol for Anesthetic Induction

Official title: Time to Loss of Consciousness With Remimazolam Versus Propofol During Anesthetic Induction for Laparoscopic Cholecystectomy: A Single-Center Randomized Controlled Trial

Run by Universidade Federal de Sergipe · NCT07717684 · Data updated 2026-11-12

This study tests whether remimazolam changes the time to loss of consciousness compared with propofol for anesthesia induction in adults undergoing elective laparoscopic gallbladder removal.

More Cholelithiasis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 59 Years
SexAll
Enrollment66 (estimated)
SponsorUniversidade Federal de Sergipe
Academic / other
Locations1 site (Aracaju, Sergipe)
StatusRecruiting
StartedAugust 21, 2026
Main results expectedAugust 2027
Study endsAugust 2027
Registry record updatedOctober 20, 2026
Trial IDNCT07717684 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–60 with ASA I–III status scheduled for elective laparoscopic cholecystectomy under TIVA.

Probably not a fit

Patients outside the age range, with ASA IV–V, BMI outside 17.5–35, or with significant organ dysfunction or neuromuscular issues may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 trial compares two intravenous drugs used to start general anesthesia in adults having elective laparoscopic cholecystectomy. Participants are randomly assigned to receive either remimazolam or propofol during induction, with standard monitoring and care throughout surgery. The trial records time to loss of consciousness, vital signs, and any adverse events during the induction period to assess hemodynamic stability and safety. By focusing on a single surgical procedure and controlled delivery, the study aims to reduce variability seen in prior comparisons. Automated delivery algorithms are used to manage drug administration to maintain consistency and safety.

Why it matters

Potential benefit: If remimazolam shows a favorable time to loss of consciousness and safety profile, it could offer a stable alternative for anesthesia induction in similar surgical settings.

How similar studies have gone: Previous comparisons of induction agents show heterogeneous results, making this focused, procedure-specific trial valuable and its success plausible if the methodology controls for confounding variables.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 18 years or older.
* American Society of Anesthesiologists (ASA) physical status I, II or III.
* Scheduled to undergo elective laparoscopic cholecystectomy under Total Intravenous Anesthesia (TIVA).

Exclusion Criteria:

* Patients younger than 18 years or older than 60 years
* American Society of Anesthesiologists (ASA) physical status IV to V
* Body Mass Index (BMI) \< 17.5 kg/m² or \> 35 kg/m²
* Hemodynamically unstable patients
* Altered or impaired renal or hepatic function
* Neuromuscular disorders
* History of alcohol or drug dependence
* History of allergy or hypersensitivity to any of the anesthetic medications utilized in the protocol

Where it's running

  • Hospital Univeritário da Universidade Federal de Sergipe
    Aracaju, Sergipe, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.